– USA, NY – Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Dr. Kevin Fitzgerald (Ph.D.), to its Board of Directors.
“We are very pleased to have Kevin join our Board of Directors. His experience transforming state-of-the-art science and novel platform technologies into commercial medicines will provide valuable perspective for Ovid’s neuroscience development programs,” said Chairman and CEO, Dr. Jeremy Levin. “Kevin’s expertise across small molecule and next-generation modalities makes him an ideal director for Ovid as we pursue innovative platforms for the development and delivery of therapeutics to the brain.”
About Dr. Kevin Fitzgerald
Dr. Fitzgerald has over 20 years of successful drug discovery experience and currently serves as the CSO, SVP, and Head of Research at Alnylam Pharmaceuticals. He joined Alnylam in 2005 after a seven-year tenure at Bristol Myers Squibb. At Alnylam, Kevin and his teams discovered and clinically validated two different modes of siRNA delivery, and he has been instrumental in the development of a novel pipeline of approved and progressing RNAi therapeutics. Dr. Fitzgerald is a prolific inventor. His co-inventorship accomplishments include many of Alnylam’s marketed and pipeline programs. He has co-authored more than 50 peer-reviewed papers, which have been published in prestigious journals including, Nature, Cell, and the New England Journal of Medicine.
“Neurological diseases represent an area of great unmet patient need, and the discovery of novel therapies is among the most exciting frontiers of therapeutic innovation. Ovid’s strategic approach to targeting and delivering therapies to the disorders of the brain bridges the technology of today with that of tomorrow,” said Dr. Fitzgerald. “I am delighted to join their Board and look forward to supporting their advances for patients with rare diseases of the central nervous system.”
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine approach to develop medicines that transform the lives of patients with neurological disorders. Ovid seeks to couple deep CNS experience with emerging advances in genetics and the pathways of the brain to build a leading, next-generation neuroscience pipeline. Ovid’s current pipeline programs include OV329, a small molecule GABA aminotransferase inhibitor for seizures associated with Tuberous Sclerosis Complex and Infantile Spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a gene therapy approach for KIF1A associated neurological disorders; and other research targets. Additionally, Ovid maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Two-Phase 3 trials for soticlestat in Dravet syndrome and Lennox-Gastaut syndrome are expected to begin in 2021.
For more information: https://ovidrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
